Skip to main content

Table 3 NVP-AUY922 biodistribution: pharmacokinetic parameters

From: NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models

  Plasma Tumor Liver Muscle Heart Lung
Cmax, μmol/L or nmol/g 14.08 ± 4.14 16.36 ± 3.84 30.94 ± 5.58 27.45 ± 6.64 36.86 ± 7.42 48.48 ± 10.11
T 1/2 elimination λ_z, hours 10.3 30 7.7 8 5.6 5.5
AUC(0-8), hours* μmol/L or hours*nmol/g 7.3 345 53 35 32 71
  1. The concentration of NVP-AUY922 was determined by high-pressure liquid chromatography/tandem mass spectrometry after a single intravenous administration of 30 mg/kg to BT-474 tumor-bearing mice. The highest concentration (Cmax), terminal half-life (T 1/2 elimination λ_z), and exposure as determined by the area under the curve (AUC) were determined for each organ, plasma, and BT-474 xenograft (tumor).